FdaApplication
NDA 209241
Identifiers
- fda_app_no: NDA209241
Properties
| Property | Value |
|---|---|
| applicant_name | NEUROCRINE BIOSCIENCES INC |
| application_type | NDA |
| approval_date | 2017-04-11 |
Revenue by product
INGREZZA
| Period | Revenue |
|---|---|
| Q1 2026 | $656.9M |
| Q1 2025 | $545.2M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (3)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| INGREZZA | VALBENAZINE TOSYLATE | EQ 60MG BASE | CAPSULE;ORAL |
| INGREZZA | VALBENAZINE TOSYLATE | EQ 80MG BASE | CAPSULE;ORAL |
| INGREZZA | VALBENAZINE TOSYLATE | EQ 40MG BASE | CAPSULE;ORAL |
3 products